Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Tauns Laboratories, Inc. ( (JP:197A) ).
TAUNS Laboratories, Inc. has announced its acquisition of CLAIRVO TECHNOLOGIES, Inc., making it a wholly-owned subsidiary. This strategic move is expected to enhance TAUNS’ capabilities in the medical device sector, especially in Software as a Medical Device (SaMD), and support its mid-term management plan. By leveraging CLAIRVO’s expertise in AI-driven medical devices and TAUNS’ strong market presence, the acquisition aims to advance healthcare through innovative diagnostic technologies and medical data research.
The most recent analyst rating on (JP:197A) stock is a Hold with a Yen544.00 price target. To see the full list of analyst forecasts on Tauns Laboratories, Inc. stock, see the JP:197A Stock Forecast page.
More about Tauns Laboratories, Inc.
TAUNS Laboratories, Inc. is a major player in the Japanese market for rapid diagnostic test kits for infectious diseases. The company is focused on solving social issues with diagnostic technology and data, particularly targeting the chronic disease field and establishing a data utilization infrastructure to accelerate medical research.
Average Trading Volume: 481,335
Technical Sentiment Signal: Sell
Current Market Cap: Yen53.91B
For detailed information about 197A stock, go to TipRanks’ Stock Analysis page.